Hisamitsu Pharmaceutical Co., Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Tosu Japan (1847)

Organization Overview

First Clinical Trial
2007
NCT00792727
First Marketed Drug
2008
menthol (Salonpas)
First NDA Approval
2008
methyl salicylate
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Hisamitsu | HISAMITSU | Hisamitsu Farmaceutica do Brasil Ltda | HISAMITSU PHARM CO

Active Ingredients

Marketed Drugs (3)

Key: Hisamitsu Pharmaceutical Co., Inc. (2) Acquired (1)

asenapine (saphris) (2019)

menthol (Salonpas) (2008 NDA)

methyl salicylate (2008 NDA)

Drugs in Phase 4 Trials (1)

Key: Hisamitsu Pharmaceutical Co., Inc. (0) Acquired (1)

methylphenidate (ritalin) (8 trials)

Drugs in Phase 3 Trials (7)

Key: Hisamitsu Pharmaceutical Co., Inc. (3) Acquired (4)

asenapine (saphris) (1 trial)

diclofenac (voltaren) (2 trials)

hkt-500 (3 trials)

ketoprofen (orudis) (2 trials)

lithium (lithonate) (1 trial)

paroxetine (paxil) (4 trials)

salicylic acid (1 trial)

Drugs in Phase 2 Trials (2)

Key: Hisamitsu Pharmaceutical Co., Inc. (1) Acquired (1)

amphetamine (Adderall) (2 trials)

htu-520 (1 trial)

Drugs in Phase 1 Trials (2)

Key: Hisamitsu Pharmaceutical Co., Inc. (0) Acquired (2)

acetazolamide (diamox) (1 trial)

recombinant human choriogonadotropin alfa (Ovidrel) (1 trial)

Indications

Approved Indications


 

Arthritis

Back Pain

Bursitis

Common Cold

Muscle Cramp

Myalgia

Osteoarthritis

Pain

Pharyngitis

Pruritus

Rhinitis

Tendinopathy

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ankle Injuries (Phase 3)

Contusions (Phase 3)

Myalgia (Phase 3)

Onychomycosis (Phase 2)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Shoulder Pain (Phase 3)

Sprains and Strains (Phase 3)

Tendinopathy (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 27
  • # of Trial APIs: 12